Growth Metrics

BeOne Medicines (ONC) Common Equity: 2014-2024

Historic Common Equity for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to $3.3 billion.

  • BeOne Medicines' Common Equity rose 20.18% to $4.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 20.18%. This contributed to the annual value of $3.3 billion for FY2024, which is 5.80% down from last year.
  • According to the latest figures from FY2024, BeOne Medicines' Common Equity is $3.3 billion, which was down 5.80% from $3.5 billion recorded in FY2023.
  • BeOne Medicines' 5-year Common Equity high stood at $6.1 billion for FY2021, and its period low was $3.3 billion during FY2024.
  • Over the past 3 years, BeOne Medicines' median Common Equity value was $3.5 billion (recorded in 2023), while the average stood at $3.8 billion.
  • Per our database at Business Quant, BeOne Medicines' Common Equity soared by 295.48% in 2020 and then decreased by 28.52% in 2022.
  • Yearly analysis of 5 years shows BeOne Medicines' Common Equity stood at $3.9 billion in 2020, then skyrocketed by 58.50% to $6.1 billion in 2021, then decreased by 28.52% to $4.4 billion in 2022, then dropped by 19.30% to $3.5 billion in 2023, then dropped by 5.80% to $3.3 billion in 2024.